Hospital Authority. Female Breast Cancer in 2023.
Available at: https://www3.ha.org.hk/cancereg/pdf/factsheet/2023/breast_2023.pdf (Last updated 28 October 2025) CHP. Breast Cancer.
Available at: https://www.chp.gov.hk/tc/healthtopics/content/25/53.html Last updated 24 October 2025
Hong Kong Cancer Registry. Top Ten Cancers.
Available at: https://www3.ha.org.hk/cancereg/tc/topten.html (Last updated 24 October 2025) CHP. Breast Cancer.
Available at: https://www.chp.gov.hk/tc/healthtopics/content/25/53.html Last updated 24 October 2025)
Hong Kong Breast Cancer Foundation. What is Breast Cancer.
Available at: https://www.hkbcf.org/en/breast_cancer/main/422/ (Last updated 24 October 2025) Hong Kong Cancer Fund. Breast Cancer.
Available at: https://www.cancer-fund.org/breast-cancer/?gad_source=1&gad_campaignid=23016788805&gbraid=0AAAAApDfHLp8dzIOXWsD0NnfJaIc99RM8&gclid=EAIaIQobChMI3Nf_14SqkAMVBxZ7Bx3B_wMMEAAYAiABEgJrC_D_BwE (Last updated 24 October 2025)
其他進一步檢驗 包括:
肝臟超聲波 掃描、骨骼掃描及 磁力共振圖像等。
影像可顯示乳房結構及乳腺組織
利用聲波造成一幅體內的圖像,可檢驗和分辨乳房腫塊是囊腫抑或腫瘤,以及查看腋下淋巴結有否腫脹
抽取一小塊細胞樣本,在顯微鏡下檢查是良性或惡性的腫瘤
某些超聲波機器的螢光幕中,醫生以顏色分辨供應到腫塊血液的流量,從而診斷良性或惡性
檢驗血液中是否含有製造癌症細胞的任何化學物質
Hong Kong Cancer Fund. Diagnosis. Available at: https://www.cancer-fund.org/breast-cancer/?cat=244 (Last updated 24 October 2025)
| 生物學亞型分類 | HR* | HER2 | 特徵 |
|---|---|---|---|
| 管腔A型 | 陽性(+) | 陰性(-) | • 細胞分裂速度較慢 • 腫瘤惡性程度較低 • 一般預後較理想 |
| 管腔B型 | 陽性(+) | 陰性(-) | • 癌細胞分裂速度較快 • 腫瘤惡性程度較高,侵略性高,比較容易出現擴散 |
| HER2型 | 陽性(+)或 陰性(-) | 陽性(+) | • 一種較為惡性的乳癌 • 侵略性高 • 擴散速度快 |
| 三陰性型 | 陰性(-) | 陰性(-) | • 癌細胞較易轉移到其他器官,尤其腦轉移 • 復發風險較高 • 預後相對較差 • 早期三陰性乳癌,復發到晚期嘅機會都比其他乳癌類別大 |
Hong Kong Cancer Fund. Understanding Breast Cancer. Available at: https://www.cancer-fund.org/wp-content/uploads/2025/04/Breast-Cancer-Booklet-Jan25C-Web.pdf (Last updated 24 October 2025)
但對於三陰性乳癌, 荷爾蒙及抗HER2的標靶治療都不適用,所以一般而言是「較惡」的乳癌
Hong Kong Breast Cancer Foundation.免疫治療 早期三陰性乳癌.
Available at: https://www.hkbcf.org/zh/media_centre/main/1050/ (Last updated 24 October 2025) American Cancer Society. Triple-negative Breast Cancer.
Available at: https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html (Last updated 24 October 2025)
HR/HER2陽性癌細胞
三陰性癌細胞
= HR(包括ER或PR) 及HER2
= 乳癌細胞
較常見於40歲以下年輕女性及遺傳性(BRCA1)乳癌
Hospital Authority. Female Breast Cancer in 2022.
Available at: https://www3.ha.org.hk/cancereg/pdf/factsheet/2022/breast_2022.pdf (Last updated 24 October 2025) American Cancer Society. Triple-negative Breast Cancer.
Available at: https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html (Last updated 24 October 2025)
局部
癌細胞仍在原發處,沒有跡象顯示 它已經擴散
92%
區域性轉移
癌細胞已經擴散至鄰近的淋巴結、 細胞組織,或器官
67%
遠端轉移
癌細胞已經擴散到身體的遠端
15%
American Cancer Society. Triple-negative Breast Cancer. Available at: https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html (Last updated 24 October 2025)
American Cancer Society. Triple-negative Breast Cancer.
Available at: https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html (Last updated 24 October 2025) Hong Kong Cancer Fund. Understanding Breast Cancer.
Available at: https://www.cancer-fund.org/wp-content/uploads/2025/04/Breast-Cancer-Booklet-Jan25C-Web.pdf (Last updated 24 October 2025)
手術、放療、化療 > 免疫治療 > PARP抑制劑 > 抗體藥物複合體 (包括TROP-2抗體藥物複合體)
Won, K. A., & Spruck, C. (2020). Triple‑negative breast cancer therapy: Current and future perspectives (Review). International journal of oncology, 57(6), 1245–1261. https://doi.org/10.3892/ijo.2020.5135
早/中期
晚期
American Cancer Society. Triple-negative Breast Cancer. Available at: https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html (Last updated 24 October 2025) NCCN Guidelines. Breast Cancer. Version 5.2025.
硬塊切除
全乳切除
腋下淋巴結切除
Hong Kong Cancer Fund. Treatments. Available at: https://www.cancer-fund.org/pink/treatment/ (Last updated 24 October 2025)
Hong Kong Cancer Fund. Treatments.
Available at: https://www.cancer-fund.org/pink/treatment/ (Last updated 24 October 2025) American Cancer Society. Radiation for Breast Cancer.
Available at: https://www.cancer.org/cancer/types/breast-cancer/treatment/radiation-for-breast-cancer.html (Last updated 24 October 2025) Hong Kong Cancer Fund. Understanding Breast Cancer.
Available at: https://www.cancer-fund.org/wp-content/uploads/2025/04/Breast-Cancer-Booklet-Jan25C-Web.pdf (Last updated 24 October 2025)
American Cancer Society. Chemotherapy for Breast Cancer .Available at: https://www.cancer.org/cancer/types/breast-cancer/treatment/chemotherapy-for-breast-cancer.html (Last updated 24 October 2025)
Hong Kong Anti-cancer Society.乳癌多面睇. .Available at: https://www.hkacs.org.hk/ufiles/BreastCancerbooklet_2019.pdf (Last updated 24 October 2025)
以PD1抑制劑為例,可:
Formosa Cancer Foundation.免疫檢查點抑制劑,帶來治療新曙光. Available at: https://elearning.canceraway.org.tw/page.php?IDno=3638 (Last updated 24 October 2025)
Drug Education Resources Centre.藥到病除:三陰性乳癌抑制劑功效勝化療. Available at: https://www.derc.org.hk/en/news-detail.php?id=1296 (Last updated 24 October 2025)
HK Breast Cancer Foundation.什麼是抗體藥物複合體?. Available at: https://www.hkbcf.org/zh/media_centre/main/1274/ (Last updated 24 October 2025) NCCN Guidelines. Breast Cancer. Version 5.2025.
台灣癌症防治網. Trop-2抗體藥物複合體在腫瘤治療的進展. Available at: http://web.tccf.org.tw/lifetype/index.php?op=ViewArticle&articleId=5246&blogId=1 (Last updated 24 October 2025)
Targeted Oncology. Sacituzumab Govitecan Benefit in HR+/HER2– Breast Cancer Not Determined by Trop-2 Levels. Available at: https://www.targetedonc.com/view/sacituzumab-govitecan-benefit-in-hr-her2-breast-cancer-not-determined-by-trop-2-levels (Last updated 24 October 2025)
與接受傳統化療患者相比, 接受TROP-2抗體藥物複合體 患者的存活期中位數 延長達~2倍
EMA. Trodelvy. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy (Last updated 24 October 2025)
Tolaney SM, et al. Oncologist. 2025:oyaf311. Hong Kong Breast Cancer Foundation.乳癌化療 白血球下降的應對. Available at: https://www.hkbcf.org/zh/media_centre/main/569/ (Last updated 5 November 2025)
HA. Smart Patient.乳癌治療的新發展及處理藥物治療的副作用. Available at: https://www.smartpatient.ha.org.hk/docs/default-source/default-document-library/20250426-%E4%B9%B3%E7%99%8C%E6%B2%BB%E7%99%82%E7%9A%84%E6%96%B0%E7%99%BC%E5%B1%95%E5%8F%8A%E8%99%95%E7%90%86%E8%97%A5%E7%89%A9%E6%B2%BB%E7%99%82%E7%9A%84%E5%89%AF%E4%BD%9C%E7%94%A8.pdf?sfvrsn=36ec85cc_4 (Last updated 24 October 2025)
ChemoCare. Eye problems. Available at: https://chemocare.com/sideeffect/dry-eye-syndrome (Last updated 5 November 2025)
HA. Smart Patient.乳癌治療的新發展及處理藥物治療的副作用. Available at: https://www.smartpatient.ha.org.hk/docs/default-source/default-document-library/20250426-%E4%B9%B3%E7%99%8C%E6%B2%BB%E7%99%82%E7%9A%84%E6%96%B0%E7%99%BC%E5%B1%95%E5%8F%8A%E8%99%95%E7%90%86%E8%97%A5%E7%89%A9%E6%B2%BB%E7%99%82%E7%9A%84%E5%89%AF%E4%BD%9C%E7%94%A8.pdf?sfvrsn=36ec85cc_4 (Last updated 24 October 2025)
HA. Smart Patient.乳癌治療的新發展及處理藥物治療的副作用. Available at: https://www.smartpatient.ha.org.hk/docs/default-source/default-document-library/20250426-%E4%B9%B3%E7%99%8C%E6%B2%BB%E7%99%82%E7%9A%84%E6%96%B0%E7%99%BC%E5%B1%95%E5%8F%8A%E8%99%95%E7%90%86%E8%97%A5%E7%89%A9%E6%B2%BB%E7%99%82%E7%9A%84%E5%89%AF%E4%BD%9C%E7%94%A8.pdf?sfvrsn=36ec85cc_4 (Last updated 24 October 2025)
HA. Smart Patient. Breast Cancer. Available at: https://www.smartpatient.ha.org.hk/smart-patient-web/disease-management/disease-information/disease/BreastCancer (Last updated 24 October 2025)